Trial Profile

Age-descending, Randomized, Placebo-controlled Phase 2 Trial in Three Sites in Sub-Saharan Africa to Assess the Safety and Immunogenicity of a Parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) Versus Placebo

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trivalent Salmonella Conjugate Vaccine Bharat Biotech/University of Maryland (Primary) ; Typhoid vaccine Vi conjugate
Indications Typhoid
Focus Adverse reactions; Pharmacodynamics
Acronyms TSCV

02 May 2025 Planned End Date changed from 30 Dec 2026 to 30 Dec 2027.
02 May 2025 Planned primary completion date changed from 5 Apr 2025 to 5 Jan 2027.
02 May 2023 Planned primary completion date changed from 31 Mar 2025 to 5 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com